Here is the time frame for Veloxis' FDA case
Veloxis now has a time frame for its pivotal court case against the US Food and Drug Administration.
BY BENJAMIN WERNER CHRISTENSEN
The public, Danish biotech company Veloxis has confirmed that the U.S. District Court for the District of Columbia has set a briefing schedule that enables complete briefing in its pending case with the FDA by March 3, 2015.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
FDA rejects Veloxis again
For abonnenter
Veloxis sues the FDA
For abonnenter
